Finally, notwithstanding one previous study on levodopa-treated Israeli PD patients reported no over effect of G2019S mutation on LID prevalence or latency [23], it will be of great relevance the investigation of LID development in LRRK2 transgenic models, including loss-of-function and knock-in. The gene discussed is LRRK2; the disease is Parkinson disease.